Call for Contributions: Empower Industry with Your Insights — CSGCT Seeks Original Submissions on Gene and Cell Therapy

VCBeatCSGCTThe official account remains committed to tracking cutting-edge developments in global gene editing, cell therapy, gene therapy, oncolytic viruses, and other fields, while building a professional platform for in-depth exchange among industry, academia, research, and clinical practice.

To pool industry wisdom, showcase innovative achievements, and promote technology transfer and industrial upgrading, we are now calling for submissions from research institutions, clinical institutions, enterprises, and industry practitioners worldwide. We sincerely invite you to share your insights and discuss the future together.

1. Technological Frontiers and Breakthroughs:Optimization and innovation of gene editing technologies (CRISPR/Cas, base editing, prime editing, etc.); process upgrades, target development, and efficacy enhancement research in cell therapies (CAR-T, CAR-NK, TCR-T, stem cell therapy, etc.); and original technological achievements in the design and delivery efficiency optimization of gene therapy vectors (viral vectors, non-viral vectors).

2. Clinical Research and Translation:Interpretation of Clinical Data, Case Analysis, and Progress Reports on Clinical Trials in Gene and Cell Therapy for Oncology, Rare Diseases, Neurodegenerative Disorders, and Autoimmune Diseases; Key Challenges and Solutions in the Process of Clinical Translation.

3. Industry Dynamics and Trends:Interpretation of global policies and regulations in the gene and cell therapy sector, analysis of investment and financing trends, corporate layout strategies, current development status and opportunities across the upstream and downstream industry chain (including raw materials, equipment, CDMO/CMO, cold-chain logistics, etc.), as well as challenges and breakthrough pathways for the commercialization of technologies.

4. Industry Reflections and Outlook:In-depth discussions on key issues such as technological bottlenecks, ethical controversies, the formulation of standards and regulations, and the construction of payment systems within the field; forward-looking analysis of future technological convergence (e.g., AI combined with gene and cell therapy) and cross-disciplinary applications.

5. Case Analysis and Practice:Case Studies of Technology Transfer in Benchmark Enterprises, Stories of Innovative Product R&D, and Reviews of Successful Clinical Applications; Research Teams’ Breakthrough Journeys and Experience Sharing.

1. Original Content:The manuscript must be an original work that has not been published on any public platform (including WeChat Official Accounts, journals, conferences, etc.). Plagiarism and appropriation are strictly prohibited. The authors are responsible for the authenticity of the manuscript and its intellectual property rights.

2. Professional and Rigorous:Ensure data accuracy and clear logic; technical manuscripts must uphold scientific rigor, while industry-focused manuscripts should demonstrate sector-specific insights and avoid superficial generalizations.

3. Format Specifications:

Word Count: Technical/clinical manuscripts are recommended to be 3,000–5,000 words, while industry/commentary pieces are suggested at 1,500–3,000 words; adjustments can be made flexibly based on content.

Structure: It is recommended to include a title, an abstract (100–200 words), the main text, references (if applicable), and author biographies. The main text may be organized into sections, and it is preferable to include relevant figures and tables that are clear and legible, with sources properly cited.

Language: Concise and fluent, with standardized use of professional terminology, balancing professionalism and readability. Submissions in English are also welcome and can be sent to the CSGCT English website.

4. Compatible Platforms:Cater to the needs of the official account’s audience (industry practitioners, researchers, investors, clinicians, etc.), avoiding overly obscure or promotional language.

1. Manuscript Submission:Please send the Word-format manuscript and author biography (including name, affiliation, position, contact information, and research interests) to both zhu.p@vcbeat.net and li.jy@vcbeat.net simultaneously. The email subject line should be uniformly formatted as “[Submission] + Article Title + Author Name”.

2. Review Cycle:Initial review will be completed within 5 working days after receipt of the manuscript. Within 10 working days after passing the initial review, comments for revision or notification of acceptance will be provided. Rejected manuscripts will be accompanied by specific reasons for rejection. Submission materials will not be returned; authors are advised to keep their own backups.

3. Copyright Notice:Upon acceptance, VCBeat’s CSGCT official account shall hold the rights of publication, compilation, and online dissemination of the manuscript, while the author retains the right of attribution. For reprints, please contact the official account via its backend to obtain authorization.

1. Platform Exposure:Accepted manuscripts will be exclusively premiered on the VCBeat CSGCT official WeChat account, reaching tens of thousands of targeted industry professionals. They will also be simultaneously distributed across multiple channels, including the VCBeat website and app, thereby enhancing the industry influence of both the authors and their affiliated institutions.

2. Professional Endorsement:High-quality submissions will be featured in the “Premium Column” of our official account, with opportunities for commentary and resharing by industry experts, helping authors build their personal professional brands.

3. Resource Matching:Distinguished authors will be invited to join VCBeat’s Gene and Cell Therapy Exchange Group, receiving priority access to online salons, offline forums, industry surveys, and other events organized by the official account, as well as opportunities to connect with industrial resources and partnerships.

For any questions regarding the call for submissions, please consult via the following methods:

WeChat: [wsmercury] (please note “Submission Inquiry” when adding)

Phone: [13691390095]

Gene and cell therapy is entering a golden age of technological explosion and industrial acceleration, where every insight has the potential to drive the industry forward. We look forward to your high-quality contributions as we jointly document industry development, share innovative achievements, and build the future of the sector together!